2022 FIT Symposium: Networking and the Job Search on Nov. 10

Save the Date! Cardiology Fellows-in-Training will have the opportunity to hear from some of Minnesota’s top cardiologists about their real-world experiences during the transition from training to practice. We will have a panel discussion for approximately 90 minutes, with time outside of that for questions and networking.


  • Catherine (Katie) Benziger, MD, MPH, FACC, FAHA – Essentia Health
  • Michelle Carlson, MD, FACC – Hennepin Healthcare
  • Selma Carlson, MD, FACC – Minneapolis VA & University of Minnesota Medical School
  • Michael Cullen, MD, FACC – Mayo Clinic
  • Andrea Elliott, MD, FACC – University of Minnesota
  • William (Bill) Katsiyiannis, MD, FACC – Minneapolis Heart Institute
  • Sheetal (Sunny) Kaul, MD, MBBS, FACC – HealthPartners
  • Carmelo Panetta, MD, FACC – University of MN Physicians
  • Retu Saxena, MD, FACC – Minneapolis Heart Institute
  • Gautam R. Shroff, MBBS, FACC – Hennepin Healthcare
  • Mengistu A. Simegn, MD, FACC, FASE – Hennepin Healthcare
  • Stephen J. Smalley, MD, FACC – Essentia Health
  • Randall (Randy) Stark, MD, FACC – Metropolitan Heart & Vascular Institute
  • Sharath S. Subramanian, MBBS, MD, FACC – Centracare Heart & Vascular Center

CME Webinar: Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs

Program Overview:

Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration, but each potentially has severe adverse events.

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs will provide cardiologists with information about the etiology of anemia in CKD, the effects on CV disease, HRQOL, and function, advantages and limitations of current management strategies, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

  • Discuss the etiology of anemia in chronic kidney disease
  • Summarize how anemia affects functioning, quality of life, and health outcomes, for patients with cardiovascular disease and chronic kidney disease
  • Assess the benefits and limitations of available modalities for treating anemia in chronic kidney disease
  • Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of anemia of chronic kidney disease

Steering Committee:

Erin Michos, MD, MHS
Associate Professor of Medicine
Division of Cardiology
Johns Hopkins School of Medicine

Matthew Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine

Jointly provided by USFH and Rockpointe.

This educational activity is supported by an educational grant from GlaxoSmithKline.

FIT Lecture Series: Mitral Valve Prolapse – When Does It Stop Being Benign? on Sept. 13

ACCMN FIT Lecture Series 09.13.22 Mitral Valve Prolapse and Mitral Annular Disjunction

Join us the second Tuesday of each month for our ongoing Fellows in Training (FIT) Lecture Series. On Tuesday, September 13th from 6-8 PM Iulia-Maria Tulai, M.D., Cardiology Fellow at the Minneapolis Heart Institute Foundation & Hennepin Healthcare, will present a talk on mitral valve prolapse.

This event is free, but registration is required. Register here and mark your calendars for the second Tuesday of every month to join us for future lectures.

Poster Contest Submissions Due Sept. 8

The 2022 Midwest Cardiovascular Forum will include a poster contest from 4:30-6:00pm on Saturday, October 29th at the Royal Sonesta Downtown Minneapolis.

  • There is Fellow, Resident, and a Medical Student tier in this contest.
  • There will be an award for first, second, and third place in each competition tier.
  • Regional representatives of the American College of Cardiology will judge all entries.
  • Submitting a Poster Abstract is free.
  • Conference Registration is free to those who have a poster accepted in the competition.
  • The deadline to submit your poster information is September 8th, 2022. The research or work submitted must be recent; June 2019-September 2022 should be the timeframe for consideration of poster work as we want to include good work that did not have an opportunity for in-person contests during the beginning of the pandemic.

Registration Opens for the 2022 Midwest Cardiovascular Forum

Attendees listen attentively to a speaker during the 2019 Midwest Cardiovascular Forum

After a two-year hiatus, the Midwest Cardiovascular Forum is returning this fall for a 1.5-day conference exploring the latest in cardiology! Sessions include topics for seasoned cardiologists, fellows-in-training, and cardiovascular team members. Join us in downtown Minneapolis from October 29-30.

Visit the Midwest Cardiovascular Forum web page for more details, and mark your calendar to attend.

ASCVD Risk Estimator Plus

ASCVD Risk Estimator Plus is an update to the American College of Cardiology ASCVD Risk Estimator that uses recent science and user feedback to help a clinician and patient build a customized risk lowering plan by estimating and monitoring change in 10 year ASCVD risk.

Use the app to:

  • Estimate a patient’s initial 10-year ASCVD risk using the pooled cohort equation
  • Receive an individualized, risk-based, intervention approach
  • Project the impact of specific interventions on a patient’s risk
  • Guide clinician-patient discussion around customizing an intervention plan
  • Update risk at follow-up based on a patient’s response to therapy using the Million Hearts Longitudinal model

Choose specific sections, or download the entire PDF Guide.

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of clinical practice guidelines without commercial support, and members volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and AHA. For some guidelines, the ACC and AHA partner with other organizations.

Intended Use
Clinical practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment.

Guiding Principles and Member Guidance: Maternal CV Care

*The following guiding principles and member guidance regarding maternal cardiovascular care are intended help members as they continue to provide the highest levels of care to patients following the recent Supreme Court decision on Dobbs vs. Jackson. They can also be accessed on ACC.org.


The ACC has long advocated for patients engaging with their doctor and the cardiovascular care team about their heart health and related risks. Shared decision-making is an essential tool in helping to navigate the risks and benefits of all treatment options, taking into account the latest science and medical evidence, social determinants of health, emphasis on health equity, and the patient’s own beliefs and goals.

While the ACC has no official policy on abortion, clinical practice guidelines and other clinical guidance tools address the dangers of pregnancy in certain patient populations at higher risk of death or serious cardiac events. As such, the College is deeply concerned about the potential implications of the Supreme Court decision regarding Dobbs vs. Jackson on the ability of patients and clinicians to engage in important shared discussions about maternal health, or to remove previously available health care options, especially given the alarming maternal health crisis in the U.S.

Similar to topics like gun violence that impact the broader medical community and the patients we serve, the ACC will continue to work with the larger House of Medicine to address specific laws and policies as they move forward that would threaten or criminalize patient-clinician discussions regarding maternal cardiovascular care.

Guiding Principles:

ACC’s mission is to transform cardiovascular care and improve heart health. We are patient-centered in our decisions and value teamwork, collaboration, professionalism and excellence.

  1. Cardiovascular disease is the leading cause of maternal mortality, a substantial and growing problem in the US. A recent study noted a 33% increase in US maternal mortality during the pandemic.
  2. Cardiovascular professionals are experts in the care of the women with cardiovascular disease who are or may become pregnant.
  3. The field of cardio-obstetrics is one of the fastest growing fields in CV medicine, and has developed a growing body of medical science, scientific literature, and practice standards (e.g. JACC five-part Cardio-Obstetrics Focus Seminar).
  4. Cardiovascular professionals bear professional responsibility to women with a variety of cardiovascular diseases which may create substantial risk of morbidity and mortality during pregnancy.
  5. Our standards of practice include counseling and shared decision-making with our patients regarding use of contraception and pregnancy termination. Important components of these decisions include knowledge of maternal risks associated with certain cardiovascular conditions and patients’ values, goals and willingness to take risk. These are among the hardest conversations that we undertake as cardiovascular professionals.
  6. We have a common interest in ensuring that cardiovascular professionals can continue to provide optimal cardiovascular care to produce the best possible outcomes for our pregnant patients with cardiovascular disease.
  7. The law must allow space for cardiovascular professionals to provide counseling to pregnant patients with cardiovascular disease that includes all medically-appropriate options, as established by medical science and practice standards.

Member Guidance:

  1. Cardiovascular professionals caring for pregnant women with heart disease should work in multi-disciplinary teams, with the patient at the center of each team. These teams are more common in large hospital systems or multispecialty clinics.
  2. Health care professionals managing the care of pregnant women with cardiovascular disease who are not supported by a large enterprise should consider referring these patients to larger systems with more layers of support and experience.
  3. In states currently or imminently restricting abortion, clinicians caring for pregnant women with heart disease should seek the counsel of risk management experts within their system and their hospital staff leadership. They should also work with their state medical societies and state representatives for the American College of Obstetrics and Gynecology (ACOG) to understand the relevant laws in their state.
  4. Cardiovascular professionals providing telehealth consultations for pregnant women with cardiovascular disease across state lines should obtain legal support from counsel in the state where the patient resides as well as their home state/institution.
  5. Cardiovascular professionals who provide care to women of childbearing age should understand the tools used to predict risk conferred by various types of cardiovascular disease and pregnancy and understand which forms of contraception are safe to use. Clinicians without relevant expertise or experience should identify the cardio-obstetric and women’s heart health programs best suited to provide care to their patients.
  6. Individual hospitals and health systems should communicate with their state medical societies and ACOG chapters concerning this issue. Angela Shuman, ACC Director of State Government Affairs, and her team can facilitate contact with the state medical society’s staff as needed.
  7. The ACC’s Cardio-Obstetrics Work Group will be developing a set of educational tools that can be used for the following purposes:
    • Formal educational presentations to colleagues
    • Educational materials for PCP and ObGyns and other medical team members
    • Educational materials which can be used to educate elected state officials (via email, social media and in-person visits)
    • Patient education materials about heart disease and pregnancy risk, cardiovascular health promotion, and wellness

NEW FIT Lecture Series: Pericarditis on Aug. 9

Join us the second Tuesday of each month for our ongoing Fellows in Training (FIT) Lecture Series. On Tuesday, August 9th from 6-8pm Kathryn F. Larson, M.D., Chief Fellow in the Division of Cardiology at Mayo Clinic will present a talk on Pericarditis.

This event is free, but registration is required. Register here and mark your calendars for the second Tuesday of every month to join us for future lectures.

Kathryn F. Larson, M.D.


Using a case-based format, we will review the basics of diagnosis, ancillary testing, and therapeutics for pericarditis. The talk will include a discussion of the 2015 ESC Guidelines on pericardial disease, as well as a brief overview of key pivotal trials in the management of pericarditis (both initial episodes and recurrence).

Professional Development Series – Meet the Inventor: How TAVI Was Born

Saturday, May 14th, 2022

10 a.m. Central | Zoom

While listening to Julio Palmaz speak at a conference in Scottsdale, Arizona in February 1989, Henning Rud Andersen was inspired to concept implanting heart valves percutaneously. Within 3 months, Dr. Andersen made and implanted the first transcatheter heart valve in an animal model. Today, TAVI is the main treatment of severe aortic stenosis in many parts of the world. Join Drs. Mohamad Alkhouli and David R. Holmes for a virtual conversation with Dr. Andersen about his extraordinary journey with TAVI.

Moderators: Mohamad Alkhouli MD, FACC and David Holmes MD

Guest: Henning Rud Andersen MD

View the event flyer here.

1 2 3 4